Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma

Phase 1

Recruiting

Conditions: Diffuse Midline Glioma, H3 K27M-Mutant

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Autologous Anti-H3.3K27M TCR-expressing T-cells

First Posted Date: 2022-07-28

Last Posted Date: 2024-10-11

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 12

Registration Number: NCT05478837

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Phase 1

Recruiting

Conditions: MDS
Hematologic Malignancy
AML
Lymphoblastic Lymphoma
Lymphoma, T-Cell
BPDCN
Lymphoma, B-Cell
Hodgkin Lymphoma
Mixed Phenotype Acute Leukemia
ALL

Interventions: Drug: Tagraxofusp
Drug: Methotrexate
Drug: Fludarabine
Drug: Dexamethasone
Drug: Azacitidine
Drug: Cytarabine IT
Drug: Cytarabine
Drug: Vincristine
Drug: Hydrocortisone

First Posted Date: 2022-07-27

Last Posted Date: 2024-12-06

Lead Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Target Recruit Count: 54

Registration Number: NCT05476770

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Hospital Orange County, Orange, California, United States
🇺🇸
UCSF School of Medicine, San Francisco, California, United States

and more 28 locations

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Phase 1

Active, not recruiting

Conditions: Tumor
Melanoma
Metastatic Melanoma

Interventions: Drug: OBX-115
Drug: Acetazolamide
Drug: Cyclophosphamide
Drug: Furosemide
Drug: Mesna
Drug: Fludarabine Phosphate

First Posted Date: 2022-07-22

Last Posted Date: 2024-10-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT05470283

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Relapsed or Refractory Large B-cell Lymphoma

Interventions: Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Dexamethasone

First Posted Date: 2022-07-15

Last Posted Date: 2024-10-04

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 30

Registration Number: NCT05459571

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

and more 13 locations

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Phase 3

Recruiting

Conditions: Mixed Phenotype Acute Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Drug: Busulfan
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine
Procedure: Haploidentical Hematopoietic Cell Transplantation
Biological: Lapine T-Lymphocyte Immune Globulin
Procedure: Matched Unrelated Donor Hematopoietic Cell Transplantation
Procedure: Lumbar Puncture
Drug: Melphalan
Drug: Methotrexate
Procedure: Multigated Acquisition Scan
Drug: Mycophenolate Mofetil
Procedure: Myeloablative Conditioning
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Biological: Rituximab
Procedure: T-Cell Depletion Therapy
Radiation: Total-Body Irradiation
Drug: Tacrolimus
Drug: Thiotepa

First Posted Date: 2022-07-14

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 435

Registration Number: NCT05457556

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 59 locations

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Phase 1

Active, not recruiting

Conditions: Mesothelioma
Mesothelioma, Malignant
Ovarian Cancer
Pancreatic Cancer
TNBC - Triple-Negative Breast Cancer
Ovarian Adenocarcinoma
Ovarian Neoplasms
Mesotheliomas Pleural
Colorectal Cancer
Triple Negative Breast Cancer

Interventions: Biological: TC-510
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2022-07-11

Last Posted Date: 2024-03-06

Lead Sponsor: TCR2 Therapeutics

Target Recruit Count: 6

Registration Number: NCT05451849

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States

and more 4 locations

CART-38 in Adult AML and MM Patients

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia (AML)
Multiple Myeloma (MM)

Interventions: Drug: 3x10(6) CART-38 cellls
Drug: 7x10(5) CART-38 cells
Drug: 7x10(6) CART-38 cells
Drug: 3x10(7) CART-38 cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2022-07-05

Last Posted Date: 2024-11-01

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 36

Registration Number: NCT05442580

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Phase 1

Recruiting

Conditions: B-Non Hodgkin Lymphoma
Leukemia, Lymphocytic, B Cell
B-Cell Leukemia
B-NHL
Acute Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
B-precursor ALL
B-All
Lymphoma, Non-Hodgkin
B-Cell Lymphoma

Interventions: Biological: CD19/CD22-CAR-transduced T cells
Drug: cyclophosphamide
Drug: fludarabine

First Posted Date: 2022-07-05

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 116

Registration Number: NCT05442515

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Phase 1

Recruiting

Conditions: Peripheral Blood Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation

Interventions: Drug: Melphalan
Drug: Sirolimus
Radiation: Total Body Irradiation (TBI)
Drug: Cyclophosphamide
Drug: Mycophenolate Mofeti
Drug: Fludarabine
Procedure: Allogeneic HSCT
Drug: Mesna
Drug: Filgrastim

First Posted Date: 2022-06-29

Last Posted Date: 2024-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 260

Registration Number: NCT05436418

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
City of Hope, Duarte, California, United States

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Phase 1

Recruiting

Conditions: Recurrent High Grade B-Cell Lymphoma
Refractory B Acute Lymphoblastic Leukemia
Refractory Indolent Non-Hodgkin Lymphoma
Recurrent Acute Lymphoblastic Leukemia
Recurrent B-Cell Prolymphocytic Leukemia
Recurrent Non-Hodgkin Lymphoma
Recurrent Transformed Chronic Lymphocytic Leukemia
Refractory Non-Hodgkin Lymphoma
Recurrent B Acute Lymphoblastic Leukemia
Refractory High Grade B-Cell Lymphoma

Interventions: Biological: Anti-CD19/CD20/CD22 CAR T-Cells
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate

First Posted Date: 2022-06-14

Last Posted Date: 2024-05-17

Lead Sponsor: Sumithira Vasu

Target Recruit Count: 36

Registration Number: NCT05418088

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy